



IBA – ACQUISITION OF OWN SHARES

Immediate Release – August 13th, 2021

Louvain-la-Neuve, Belgium, August 13th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 14.254 IBA shares on Euronext Brussels in the period from August 6th, 2021 up to and including August 12th, 2021, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
6/8/2021	1,469	16.52 €	16.44 €	16.58 €	24,268.17 €
9/8/2021	3,380	16.43 €	16.32 €	16.50 €	55,524.95 €
10/8/2021	4,500	16.50 €	16.38 €	16.68 €	74,241.45 €
11/8/2021	2,100	16.91 €	16.64 €	17.20 €	35,501.55 €
12/8/2021	2,805	16.87 €	16.66 €	17.18 €	47,315.02 €
TOTAL	14,254	16.62 €	16.32 €	17.20 €	236,851.14 €

The total number of shares purchased under this program therefore amounts to 137.132. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

	Shares	Voting rights
IBA Investments SCRL	400,503	400,503
IBA SA	557,501	620,870
Total - Treasury shares	958,004	1,021,373
Total - Issued shares	30,133,920	38,254,747
Treasury shares in %	3.18%	2.67%



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA

Christian Matton,
Chief Legal Officer

shareholderrelations@iba-group.com